Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The cardiovascular effects of ertugliflozin, an inhibitor of sodium-glucose cotransporter 2, have not been established. METHODS: In a multicenter, double-blind trial, we randomly assigned patients with type 2 diabetes and atherosclerotic cardiovascular disease to receive 5 mg or 15 mg of ertugliflozin or placebo once daily. With the data from the two ertugliflozin dose groups pooled for analysis, the primary objective was to show the noninferiority of ertugliflozin to placebo with respect to the primary outcome, major adverse cardiovascular events (a composite of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke). The noninferiority margin was 1.3 (upper boundary of a 95.6% confidence interval for the hazard ratio [ertugliflozin vs. placebo] for major adverse cardiovascular events). The first key secondary outcome was a composite of death from cardiovascular causes or hospitalization for heart failure. RESULTS: A total of 8246 patients underwent randomization and were followed for a mean of 3.5 years. Among 8238 patients who received at least one dose of ertugliflozin or placebo, a major adverse cardiovascular event occurred in 653 of 5493 patients (11.9%) in the ertugliflozin group and in 327 of 2745 patients (11.9%) in the placebo group (hazard ratio, 0.97; 95.6% confidence interval [CI], 0.85 to 1.11; P<0.001 for noninferiority). Death from cardiovascular causes or hospitalization for heart failure occurred in 444 of 5499 patients (8.1%) in the ertugliflozin group and in 250 of 2747 patients (9.1%) in the placebo group (hazard ratio, 0.88; 95.8% CI, 0.75 to 1.03; P = 0.11 for superiority). The hazard ratio for death from cardiovascular causes was 0.92 (95.8% CI, 0.77 to 1.11), and the hazard ratio for death from renal causes, renal replacement therapy, or doubling of the serum creatinine level was 0.81 (95.8% CI, 0.63 to 1.04). Amputations were performed in 54 patients (2.0%) who received the 5-mg dose of ertugliflozin and in 57 patients (2.1%) who received the 15-mg dose, as compared with 45 patients (1.6%) who received placebo. CONCLUSIONS: Among patients with type 2 diabetes and atherosclerotic cardiovascular disease, ertugliflozin was noninferior to placebo with respect to major adverse cardiovascular events. (Funded by Merck Sharp & Dohme and Pfizer; VERTIS CV ClinicalTrials.gov number, NCT01986881.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The trial of once-weekly exenatide demonstrated a directionally favorable effect on MACE but narrowly missed statistical significance.644”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [644]
In the citing paper
“In the CVOTs Harmony Outcomes (albiglutide vs placebo), EXSCEL (exenatide LA vs placebo), and AMPLITUDE-O (efpeglenatide vs placebo), there were numerically fewer strokes, but HRs were not significant.472,641,644”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [644]
In the citing paper
“The SGLT2i cardiovascular outcome trials (CVOTs) have reported DKA rates of 0.1 -0.6% compared with rates of < 0.1 -0.3% with placebo (143 -147), with very low rates in the HF (148 -151) and CKD (152,153) outcome studies.”
In the citing paper
“In the Evaluation of Ertugli fl ozin Ef fi cacy and Safety CVOT (VERTIS CV), which recruited exclusively people with established CVD and type 2 diabetes, ertugli fl ozin was similar to placebo with respect to the primary MACE outcome and all key secondary outcomes (including a composite kidney outcome) except for HHF (146).”
In the citing paper
“While there was a trend for bene fi t for the key secondary endpoint of cardiovascular death or heart failure hospitalization, this did not meet statistical signi fi cance (HR: 0.88; 95% CI: 0.75 -1.03).”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [91]
18 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Neal, B., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Erondu, N., Shaw, W., Law, G., Desai, M., & Matthews, D. R. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611925 · Cited by 7,830
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
Wiviott, S. D., Raz, I., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., Silverman, M. G., Zelniker, T. A., Kuder, J. F., Murphy, S. A., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1812389 · Cited by 6,382
Self-citationCanagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
Perkovic, V., Jardine, M. J., Neal, B., Bompoint, S., Heerspink, H. J. L., Charytan, D. M., Edwards, R., Agarwal, R., Bakris, G., Bull, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1811744 · Cited by 6,189
Self-citationEmpagliflozin and Progression of Kidney Disease in Type 2 Diabetes
Wanner, C., Inzucchi, S. E., Lachin, J. M., Fitchett, D., von Eynatten, M., Mattheus, M., Johansen, O. E., Woerle, H. J., Broedl, U. C., & Zinman, B. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1515920 · Cited by 3,655
Mortality and cardiovascular disease in type 1 and type 2 diabetes
Rawshani, A., Rawshani, A., Franzén, S., Eliasson, B., Svensson, A.-M., Miftaraj, M., McGuire, D. K., Sattar, N., Rosengren, A., & Gudbjörnsdottir, S. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1608664 · Cited by 1,389
Self-citationKDOQI clinical practice guideline for diabetes and CKD: 2012 update
(2012) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2012.07.005 · Cited by 1,320
Changing epidemiology of type 2 diabetes mellitus and associated chronic kidney disease
Thomas, M. C., Cooper, M. E., & Zimmet, P. (2016) · Nature Reviews Nephrology · doi:10.1038/nrneph.2015.173 · Cited by 742
Interim analysis: The alpha spending function approach
Demets, D. L., & Lan, K. K. G. (1994) · Statistics in Medicine · doi:10.1002/sim.4780131308 · Cited by 564
Cannon, C. P., McGuire, D. K., Pratley, R., Dagogo-Jack, S., Mancuso, J., Huyck, S., Charbonnel, B., Shih, W. J., Gallo, S., Masiukiewicz, U., et al. (2018) · American Heart Journal · doi:10.1016/j.ahj.2018.08.016 · Cited by 203
Self-citation
Research works printed but not linked: 1
- Food and Drug Administration. Guidance for industry: diabetes mellitus — evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes. Fed Regist 2008;73(245):77724-77725 (https://www.govinfo.gov/content/pkg/FR-2008-12-19/pdf/E8-30086.pdf).
Cited by
Items 601–700 of 1,001
Banerjee, M., Pal, R., Maisnam, I., & Mukhopadhyay, S. (2024) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2024.102943 · Cited by 14
Surprises in cardiology: efficacy of gliflozines in heart failure even in the absence of diabetes
Bragagni, A., Piani, F., & Borghi, C. (2021) · European Heart Journal Supplements · doi:10.1093/eurheartj/suab094 · Cited by 14
“In contrast with the other molecules of SGLT2i class, ertuglifozin in the VERTISCV trial did not demonstrate, despite having the same effects on glycaemic control, any benefit in reducing deaths from cardiovascular events and in the incidence of major cardiovascular events in diabetic patients, compared to placebo.(4)…”
ResultGuarding the heart: How SGLT-2 inhibitors protect against chemotherapy-induced cardiotoxicity
Vafa, R. G., Sabahizadeh, A., & Mofarrah, R. (2023) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2023.102350 · Cited by 16
Taheri, S. (2023) · World Journal of Nephrology · doi:10.5527/wjn.v12.i5.182 · Cited by 14
Jarraya, F., Niang, A., Bagha, H., Tannor, E. K., Sumaili, E. K., Wan, D. I. M., Chothia, M., Mengistu, Y. T., Kaze, F. F., Ulasi, I., et al. (2023) · Kidney International Reports · doi:10.1016/j.ekir.2023.12.019 · Cited by 15
Antidiabetic Treatment and Prevention of Ischemic Stroke: A Systematic Review
Prentza, V., Pavlidis, G., Ikonomidis, I., Pililis, S., Lampsas, S., Kountouri, A., Pliouta, L., Korakas, E., Thymis, J., Palaiodimou, L., et al. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13195786 · Cited by 15
“The hazard ratio for a secondary outcome of stroke was 1.06 (95% CI, 0.82–1.37), consistent with findings from other SGLT-2i cardiovascular outcomes RCTs [33].”
ResultInfluentialSpiazzi, B. F., Piccoli, G. F., Wayerbacher, L. F., Lubianca, J. P. N., Scalco, B. G., Scheffler, M. H., Fraga, B. L., Colpani, V., & Gerchman, F. (2024) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2024.111933 · Cited by 16
Cardiovascular Disease & Diabetes Statistics in Korea: Nationwide Data 2010 to 2019
Kim, J. H., Lee, J., Han, K., Kim, J., & Kwon, H. (2024) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2024.0275 · Cited by 13
Shah, M. U., Roebuck, A., Srinivasan, B., Ward, J. K., Squires, P. E., Hills, C. E., & Lee, K. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1499681 · Cited by 23
Novel Antidiabetic Drugs and Risk of Venous Thromboembolism: A Literature Review
Chen, Q., Anijs, R. J. S., Verlaan, J. P. L., Scheres, L. J. J., Klok, F. A., & Cannegieter, S. C. (2025) · Seminars in Thrombosis and Hemostasis · doi:10.1055/a-2546-0353 · Cited by 15
Cannarella, R., Rubulotta, M., Cannarella, V., Vignera, S. L., & Calogero, A. E. (2025) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2025.06.010 · Cited by 15
SGLT-2 inhibitors: A step forward in the treatment of heart failure with reduced ejection fraction
Silva‐Cardoso, J., Andrade, A., Brito, D. A., Ferreira, J., Fonseca, C., Peres, M., Franco, F., & Moura, B. (2021) · Revista Portuguesa de Cardiologia (English Edition) · doi:10.1016/j.repc.2021.02.010 · Cited by 15
Vrachatis, D. A., Papathanasiou, K. A., Iliodromitis, K. E., Giotaki, S. G., Kossyvakis, C., Raisakis, K., Kaoukis, A., Lambadiari, V., Avramides, D., Reimers, B., et al. (2021) · Drugs · doi:10.1007/s40265-021-01565-3 · Cited by 14
“RCTs Zelniker; 2020 [96] DAPA Known ASCVD or MRF + T2DM 8582 8578 37 4.2 ya New AF HR: 0.77 (0.64–0.92) Yes 0.005 AF events HR: 0.81 (0.68–0.95) 0.009 EMPERIAL Reduced [113] NCT03448419 EMPA HFrEF ± T2DM 156 156 26 12 w AF as SAE Placebo vs. SGLT2i: 1/156 vs. 0/155 N/A N/A EMPERIAL Preserved [113] NCT03448406 EMPA HFp…”
InfluentialNational Asthma Education and Prevention Program 2020 Guidelines: What’s Important for Primary Care
Murphy, M. (2021) · The Journal of Family Practice · doi:10.12788/jfp.0219 · Cited by 16
The pleiotropic cardiovascular effects of sodium-glucose cotransporter-2 inhibitors
Tanna, M. S., & Goldberg, L. R. (2021) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000922 · Cited by 14
“Ertugliflozin was noninferior to placebo with respect to the primary outcome of MACE (composite of cardiovascular death, nonfatal myocardial infarction or nonfatal stroke), establishing cardiovascular safety [6].”
MethodBarraclough, J., Patel, S., Yu, J., Neal, B. C., & Arnott, C. G. (2021) · Cells · doi:10.3390/cells10102699 · Cited by 14
“The proportion of individuals with established ASCVD in each trial is outlined in Table 1 and ranges from 40.6% in DECLARE-TIMI to 100% in EMPA-REG Outcome [2] and VERTIS [8].”
BackgroundMethodInfluentialThe SGLT-2 Inhibitors in Personalized Therapy of Diabetes Mellitus Patients
Tilinca, M. C., Tiucă, R. A., Ţilea, I., & Varga, A. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11121249 · Cited by 15
“The multicenter, double‐blind, randomized controlled VERTIS‐CV trial tested the ef‐ fect of ertugliflozin on patients with type 2 DM and established ASCVD, and showed the non‐inferiority of this SGLT‐2i compared to a placebo, in terms of MACE and reduction in risk of the first hospitalization for HF, but not for known…”
BackgroundMethodInfluentialMeta-Analysed Numbers Needed to Treat of Novel Antidiabetic Drugs for Cardiovascular Outcomes
Wolff, G., Lin, Y., Akbulut, C., Brockmeyer, M., Parco, C., Hoss, A., Sokolowski, A., Westenfeld, R., Kelm, M., Roden, M., et al. (2022) · ESC Heart Failure · doi:10.1002/ehf2.14213 · Cited by 13
Jha, K. K., Adhikari, R., Tasdighi, E., Osuji, N., Rajan, T., & Blaha, M. J. (2022) · Current Atherosclerosis Reports · doi:10.1007/s11883-022-01066-y · Cited by 13
Ma, Y., Lin, C., Cai, X., Hu, S., Zhu, X., Lv, F., Yang, W., & Ji, L. (2023) · Acta Diabetologica · doi:10.1007/s00592-022-02022-7 · Cited by 13
“This trend was also demonstrated in individual outcome trials such as CANVAS program, SCORED, EMPA-REG outcome and VERTIS-CV.”
BackgroundChen, H., Yang, Y., Meng, R., & Liu, X. (2023) · ESC Heart Failure · doi:10.1002/ehf2.14297 · Cited by 13
Fu, Y., Xu, L., Zhang, H., Ding, N., Zhang, J., Ma, S., Yang, A., Hao, Y., Gao, Y., & Jiang, Y. (2023) · Journal of Inflammation Research · doi:10.2147/jir.s393788 · Cited by 13
“Identification of Therapeutic Small Molecular Agents Based on the DEGs Whereas several drugs approved for treating diabetes were of benefit for AS, their effect is controversial.(23) For instance, though peroxisome proliferator-activated receptor (PPAR) γ agonist, pioglitazone benefits in the reduction and stabilizati…”
BackgroundDoi, Y., Hamano, T., Yamaguchi, S., Sakaguchi, Y., Kaimori, J., & Isaka, Y. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15191 · Cited by 13
Meta‐analysis of Association between Newer Glucose‐Lowering Drugs and Risk of Parkinson's Disease
Tang, H., Lu, Y., Okun, M. S., Donahoo, W. T., Ramirez‐Zamora, A., Wang, F., Huang, Y., Chen, W., Virnig, B. A., Bian, J., et al. (2023) · Movement Disorders Clinical Practice · doi:10.1002/mdc3.13893 · Cited by 16
Sagris, D., Ntaios, G., & Milionis, H. J. (2023) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2022-329149 · Cited by 13
“…in patients with stroke, data extracted from RCTs including patients with diabetes, 82–84 heart failure 80 81 or chronic kidney disease 86–91 who had a medical history of ischaemic stroke point towards their potential importance in patients with stroke and comorbidities even in the…”
BackgroundMethodBudoff, M. J., Davis, T. M. E., Palmer, A. G., Frederich, R. C., Lawrence, D. E., Liu, J., Gantz, I., & Derosa, G. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01033-x · Cited by 13
Self-citationTang, H., Kimmel, S. E., Smith, S. M., Cusi, K. J., Shi, W., Gurka, M. J., Winterstein, A. G., & Guo, J. S. (2022) · Diabetes Care · doi:10.2337/dc21-1722 · Cited by 14
Report from the CVOT Summit 2020: new cardiovascular and renal outcomes
Schnell, O., Cos, X., Cosentino, F., Forst, T. M., Giorgino, F., Heersprink, H. J. L., Kosiborod, M., Wanner, C., & Standl, E. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01254-1 · Cited by 15
Self-citationLandgraf, R., Aberle, J., Birkenfeld, A. L., Gallwitz, B., Kellerer, M., Klein, H., Müller-Wieland, D., Nauck, M. A., Wiesner, T., & Siegel, E. (2022) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-1624-3449 · Cited by 12
Tian, L., Ai, S., Zheng, H., Yang, H., Zhou, M., Tang, J., Liu, W., Zhao, W., & Wang, Y. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.986186 · Cited by 14
“However, hospitalization for heart failure was not reported in DAPA-CKD, and renal composite outcomes were not reported in the SOLOIST-WHF and DAPAHF trials.”
InfluentialDisruption of COMMD1 accelerates diabetic atherosclerosis by promoting glycolysis
Zhang, L., Li, L., Li, Y., Jiang, H., Sun, Z., Zang, G., Qian, Y., Shao, C., & Wang, Z. (2023) · Diabetes and Vascular Disease Research · doi:10.1177/14791641231159009 · Cited by 13
“Diabetes is associated with severe atherosclerosis, and increases the risk of atherosclerosis and the subsequent occurrence of coronary artery disease, stroke, and so on.(1,2) Atherosclerosis is a chronic inflammatory disease involving lipid deposition in the vascular wall and the formation of discrete or sheeted athe…”
BackgroundCardio‐renal‐metabolic disease in primary care setting
Ibrahim, M. A., Ba-Essa, E. M., Baker, J. C., Cahn, A., Ceriello, A., Cosentino, F., Davies, M. J., Eckel, R. H., Gaal, L. V., Gæde, P., et al. (2023) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3755 · Cited by 14
Self-citationXu, B., Kang, B., & Zhou, J. (2024) · Clinical Research in Cardiology · doi:10.1007/s00392-024-02386-6 · Cited by 12
“In the pivotal cardiovascular outcome trials EMPA-REG OUTCOME [13], DECLARE–TIMI 58 [14], VERTIS CV [15], and CANVAS program [16], SGLT2 inhibitors reduced major adverse cardiovascular events, as well as showed benefit for hospitalization for heart failure or cardiovascular death.”
InfluentialHeart Failure with Preserved Ejection Fraction: How to Deal with This Chameleon
Lucà, F., Oliva, F. G., Abrignani, M. G., Fusco, S. A. D., Gori, M., Giubilato, S., Ceravolo, R., Temporelli, P. L., Cornara, S., Rao, C. M., et al. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13051375 · Cited by 16
Metabolism and bioenergetics in the pathophysiology of organ fibrosis
Miguel, V., Alcalde‐Estévez, E., Sirera, B., Rodríguez‐Pascual, F., & Lamas, S. (2024) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2024.06.001 · Cited by 13
Nair, L., Asuzu, P., & Dagogo-Jack, S. E. (2024) · Journal of the Endocrine Society · doi:10.1210/jendso/bvae116 · Cited by 14
“The studies with SGLT-2 inhibitors showed a variable 3% to 14% relative risk reductions for major adverse cardiovascular events (MACE) and a consistent ∼ 30% relative risk reductions for hospitalization for heart failure across individual drugs [132-135].”
BackgroundSelf-citationHamid, A. K., Tayem, A. A., Al-Aish, S. T., Sakini, A. S. A., Hadi, D. D., & Al-Aish, R. T. (2024) · Therapeutic Advances in Cardiovascular Disease · doi:10.1177/17539447241289067 · Cited by 12
Lim, S. K., Bae, J. H., Oh, H., Hwang, I., Yoon, Y. E., & Cho, G. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02463-0 · Cited by 15
Haider, S. H., Irfan, A., Sheikh, S. M., Larik, M. O., Raza, A., & Khabir, Y. (2025) · Clinical Medicine Insights Cardiology · doi:10.1177/11795468251347777 · Cited by 12
“8,9 This trend of varying risks of amputations and fractures on treatment with SGLT2 inhibitors strengthens the stance that this class of drug has no appreciable effects on amputations and fractures.”
From Current Therapeutics to Multitarget Ligands: A Review of Diabetes Pharmacological Treatments
Cabré, F., Centelles, J. J., & Cascante, M. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17091125 · Cited by 16
“In cardiovascular or trials, SGLT2 inhibitors are associated with a 30–35% lower risk of heart failure hospitalization [100–103].”
Kadowaki, T., Yamamoto, F., Taneda, Y., Naito, Y., Clark, D., Lund, S. S., Okamura, T., & Kaku, K. (2021) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2021.1898585 · Cited by 13
“Five trials investigated the following four SGLT2 inhibitors: empagliflozin (EMPA-REG OUTCOME [42–42–47]), canagliflozin (CANVAS Program [48–51] and CREDENCE [52–54]), dapagliflozin (DECLARE-TIMI 58 [55–55–58]), and ertugliflozin (VERTIS CV) [59,60].”
BackgroundSodium-glucose cotransporter 2 inhibition in non-diabetic kidney disease
Almaimani, M. K., Sridhar, V. S., & Cherney, D. Z. I. (2021) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000000724 · Cited by 13
Self-citationQiu, M., Ding, L., & Zhou, H. (2021) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-021-00484-8 · Cited by 12
“All the trials included in this network meta-analysis were placebo-controlled RCTs: the SCORED trial [1] assessed sotagliflozin in patients with T2D and CKD, the SOLOIST-WHF trial [2] assessed sotagliflozin in patients with T2D and HF, the VERTIS CV trial [6] assessed ertugliflozin in patients with T2D, the DAPA-CKD t…”
ResultSodium-glucose cotransporter type 2 inhibitors: successful running after two hares
Перепеч, Н. Б., & Mikhailova, I. E. (2021) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2021-4534 · Cited by 13
Passantino, A., Rizzo, C., Scrutinio, D., & Palazzuoli, A. (2021) · Heart Failure Reviews · doi:10.1007/s10741-021-10186-7 · Cited by 13
“1 3 double-blind, multicenter trial that targeted patients with T2DM and established atherosclerotic CV disease in which the effects of ertugliflozin with placebo on CV, renal, and metabolic outcomes were compared [9].”
BackgroundLee, S. E., Nam, H., Choi, H. S., Kim, H., Kyoung, D., & Kim, K. (2022) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2021.0160 · Cited by 14
Can SGLT2 inhibitors answer unmet therapeutic needs in chronic kidney disease?
Nicola, L. D., Cozzolino, M. G., Genovesi, S., Gesualdo, L., Grandaliano, G., & Pontremoli, R. (2022) · Journal of Nephrology · doi:10.1007/s40620-022-01336-7 · Cited by 17
Scholtes, R. A., Mosterd, C. M., Hesp, A. C., Smits, M. M., Heerspink, H. J. L., & van Raalte, D. H. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14864 · Cited by 14
The Benefit of Sodium-Glucose Co-Transporter Inhibition in Heart Failure: The Role of the Kidney
Gronda, E., Vanoli, E., Iacoviello, M., Caldarola, P., Gabrielli, D., & Tavazzi, L. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231911987 · Cited by 13
Hsieh, C., & Sung, S. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms24010351 · Cited by 15
Cesaro, A., Acerbo, V., Vetrano, E., Signore, G., Scherillo, G., Rotolo, F. P., Michele, G. D., Scialla, F., Raucci, G., Panico, D., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24098099 · Cited by 14
“In the Evaluation of Ertugliflozin Efficacy and Safety Cardiovascular Outcomes Trial (VERTIS CV), ertugliflozin was noninferior to placebo with respect to MACE [3].”
MethodInfluentialBelančić, A., & Majanović, S. K. (2023) · Diabetology · doi:10.3390/diabetology4030022 · Cited by 15
Exploring SGLT-2 Inhibitors: Benefits beyond the Glucose-Lowering Effect—What Is New in 2023?
Young, C. F., Farnoudi, N., Chen, J., & Shubrook, J. H. (2023) · Endocrines · doi:10.3390/endocrines4030045 · Cited by 14
Zhao, L., Huang, J.-N., Qiu, M., Ding, L., Zhan, Z., & Ning, J. (2021) · Medicine · doi:10.1097/md.0000000000027362 · Cited by 16
“Nowadays, the new evidence from relevant randomized trials, such as the SOLOIST-WHF trial,[4] the SCORED trial,[5] and the VERTIS CV trial,[6] is available.”
InfluentialThe year in cardiovascular medicine 2021: diabetes and metabolic disorders
Cosentino, F., Bhatt, D. L., Marx, N., & Verma, S. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab876 · Cited by 13
“Aldosterone receptor antagonism and cardiovascular events in patients with type 2 diabetes and kidney disease The long-term effects on the kidney and CV outcomes of finerenone, a non-steroidal, selective mineralocorticoid receptor antagonist, were investigated in the multicentre FIDELIO-DKD trial in patients with T2D…”
InfluentialSelf-citationGeorgianos, P. I., Vaios, V., Roumeliotis, S. K., Leivaditis, K., Eleftheriadis, T., & Liakopoulos, V. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12020223 · Cited by 15
Meta-analysis of the association between new hypoglycemic agents and digestive diseases
Wang, Y., Lin, J.-H., & Yang, C.-S. (2022) · Medicine · doi:10.1097/md.0000000000030072 · Cited by 12
“, EMPA-REG OUTCOME [NCT01131676],[10] CANVAS [NCT01032629],[11] CANVAS-R [NCT01989754],[11] DECLARE–TIMI 58 [NCT01730534],[12] VERTIS CV [NCT01986881],[13] CREDENCE [NCT02065791],[14] DAPA-HF [NCT03036124],[15] DAPACKD [NCT03036150],[16] and EMPEROR-Reduced [NCT03057977][17]), 7 GLP1RA trials (i.”
Rahil, A., Bhavsar, T., Fatima, R., Rajkumar, A., Kumar, J., Majidan, H. A., Gajjala, N., LEFRANC, W., Deeksha, F., Lingegowda, H., et al. (2025) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2025.1543153 · Cited by 16
Chen, J.-J., Hsu, C., Hung, C., Liang, C., Su, K., Carvalho, A. F., Stubbs, B., Chen, Y.-W., Chen, T., Lei, W., et al. (2025) · Pharmaceuticals · doi:10.3390/ph18050735 · Cited by 14
Starr, J. A., Pinner, N. A., Lisenby, K. M., & Osmonson, A. J. (2021) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2527 · Cited by 15
Cardiovascular Outcome Trials with Glucose-Lowering Drugs
Thethi, T. K., Bilal, A., & Pratley, R. E. (2021) · Current Cardiology Reports · doi:10.1007/s11886-021-01505-3 · Cited by 11
Self-citationCherney, D. Z. I., Cosentino, F., Pratley, R. E., Dagogo-Jack, S. E., Frederich, R. C., Maldonado, M., Liu, J., Pong, A., Liu, C., Cannon, C. P., et al. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14677 · Cited by 11
“Details of patient participant disposition and trial conduct have been reported.(5,8) The numbers of patients defined by the KDIGO CKD low-, moderate- and high-/”
BackgroundMethodSelf-citationNusca, A., Piccirillo, F., Bernardini, F., Filippis, A. D., Coletti, F., Mangiacapra, F., Ricottini, E., Melfi, R., Gallo, P., Cammalleri, V., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23137261 · Cited by 14
Distinctive effects of SGLT2 inhibitors on angiogenesis in zebrafish embryos
Huttunen, R. J., Sainio, A., Hjelt, A., Haapanen-Saaristo, A.-M., Määttä, J. A., Rummukainen, P., Paatero, I., & Järveläinen, H. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113882 · Cited by 12
Nelson, A. J., Pagidipati, N. J., Kelsey, M. D., Ardissino, M., Aroda, V. R., Cavender, M. A., Lópes, R. D., Al‐Khalidi, H. R., Braceras, R., Gaynor, T., et al. (2022) · American Heart Journal · doi:10.1016/j.ahj.2022.10.079 · Cited by 11
Self-citationCVOT Summit 2022 Report: new cardiovascular, kidney, and glycemic outcomes
Schnell, O., Battelino, T., Bergenstal, R. M., Birkenfeld, A. L., Ceriello, A., CHENG, A. Y. Y., Davies, M. J., Edelman, S. V., Forst, T. M., Giorgino, F., et al. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-01788-6 · Cited by 13
Unexplained Residual Risk In Type 2 Diabetes: How Big Is The Problem?
Neppala, S., Rajan, J., Yang, E., & DeFronzo, R. A. (2024) · Current Cardiology Reports · doi:10.1007/s11886-024-02055-0 · Cited by 12
SGLT-2 Inhibitors in Heart Failure: Guide for Prescribing and Future Perspectives
Garla, V. V., Butler, J., & Lien, L. F. (2021) · Current Cardiology Reports · doi:10.1007/s11886-021-01486-3 · Cited by 13
Benefits of sodium glucose cotransporter 2 inhibitors across the spectrum of cardiovascular diseases
Gulsin, G. S., Graham-Brown, M. P. M., Squire, I. B., Davies, M. J., & McCann, G. P. (2021) · Heart · doi:10.1136/heartjnl-2021-319185 · Cited by 12
Li, K., Kong, R., Ma, L., Cao, Y. Q., Li, W., Chen, R., Gong, K., & Jiang, L. (2022) · Bioscience Reports · doi:10.1042/bsr20221394 · Cited by 11
Zhang, Y., Wang, J., Jiang, L., Wang, T., Li, Z., Fu, X., Huang, W., Xiao, Y., Wang, S., & Zhao, J. (2022) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-022-00929-3 · Cited by 11
Renoprotection with sodium‐glucose cotransporter‐2 inhibitors in children: Knowns and unknowns
Jiang, B., Cheng, Z., Liu, F., Li, Q., Fu, H., & Mao, J. (2021) · Nephrology · doi:10.1111/nep.13979 · Cited by 11
“ertugliflozin).(17,18) The outcomes of these famous RCTs are summarized in Table 1.”
BackgroundCanagliflozin and myocardial oxidative stress: SGLT1 inhibition takes centre stage
Schiattarella, G. G., & Bode, D. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab519 · Cited by 12
Kani, R., Miyamoto, Y., Saito, T., Watanabe, A., Matsubara, K., Ejiri, K., Iwagami, M., Slipczuk, L., Hosseini, K., Fujisaki, T., et al. (2025) · International Journal of Cardiology · doi:10.1016/j.ijcard.2025.133079 · Cited by 10
Wahinya, M., & Khan, Z. U. (2023) · Cureus · doi:10.7759/cureus.37388 · Cited by 13
“Some postulated mechanisms of action of SGLT2 inhibitors that are beneficial in HF include their natriuresis and osmotic diuretic effects, which reduce the preload and afterload in HF [11], reduce the blood pressure [12,13], improve the cardiac metabolism and overall performance [14], preventing cardiac remodeling [15…”
BackgroundWang, Q., Yu, J., Deng, W., Liu, C., Yang, J., Li, Y., Cai, G., Chen, X., & Dong, Z. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1372421 · Cited by 15
Lin, Y., Zhang, Y., Wang, S., Cao, L. S., Zhao, R., Ma, X., Yang, Q., Zhang, L.-Y., & Yang, Q. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1443045 · Cited by 11
Lin, D. S., Lee, J., Huang, K., Lin, T., & Lo, H.-Y. (2024) · Diabetologia · doi:10.1007/s00125-024-06257-7 · Cited by 11
“Patients with eGFR 30 ml/min 1.73 m 2 have been excluded from CVOTs of SGLT2i use in individuals with diabetes [1, 3–5].”
InfluentialCimellaro, A., Cavallo, M., Mungo, M., Suraci, E., Spagnolo, F., Addesi, D., Pintaudi, M., & Pintaudi, C. (2024) · Medicina · doi:10.3390/medicina60091542 · Cited by 12
Obaid, M. I., Shahzad, M. S., Latif, F., Khan, M. H., Akram, M., Rizvi, S. A. M., Nasrullah, R. M. U., Asad, D., & Obaid, M. A. (2024) · Future Science OA · doi:10.1080/20565623.2024.2400797 · Cited by 11
Neumiller, J. J., Herrin, J. S., SWARNA, K. S., Polley, E. C., Galindo, R. J., Umpierrez, G. E., Deng, Y., Ross, J. S., Mickelson, M. M., & McCoy, R. G. (2024) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.0000000587 · Cited by 13
Sinclair, M. R., Ardehali, M. M., Diamantidis, C. J., & Corsino, L. (2024) · Frontiers in Public Health · doi:10.3389/fpubh.2024.1412874 · Cited by 10
Bellos, I., Marinaki, S., Λάγιου, Π., & Benetou, V. (2024) · Biomolecules · doi:10.3390/biom15010039 · Cited by 12
Wu, D., Hsu, B., & Lin, Y. (2025) · Tzu Chi Medical Journal · doi:10.4103/tcmj.tcmj_275_24 · Cited by 14
Liu, F., & Cai, H. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1583267 · Cited by 10
An, Y., & Zhang, H. (2025) · American Journal of Nephrology · doi:10.1159/000546079 · Cited by 10
The use of SGLT2 inhibitors in older people: What is important?
Armentaro, G., Maio, R., Bencivenga, L., Okoye, C., Severini, G., Cassano, V., Zanobbi, V., Condoleo, V., Bellelli, G., Rengo, G., et al. (2025) · Aging Clinical and Experimental Research · doi:10.1007/s40520-025-03156-8 · Cited by 10
Chronic Coronary Artery Disease
Kittleson, M. M. (2025) · Annals of Internal Medicine · doi:10.7326/annals-25-03512 · Cited by 12
Pharmacokinetics and Pharmacodynamics of Ertugliflozin in Healthy Japanese and Western Subjects
Li, Y., Nucci, G., Yamamoto, Y., Fediuk, D. J., & Sahasrabudhe, V. (2021) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.908 · Cited by 10
Three new categories of hypoglycaemic agents and various cardiovascular diseases: A meta‐analysis
Liao, X., Li, W., Peng, Z., Yu, H., & Tan, J. (2021) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.13588 · Cited by 10
Dagogo-Jack, S. E., Cannon, C. P., Cherney, D. Z. I., Cosentino, F., Liu, J., Pong, A., Gantz, I., Frederich, R. C., Mancuso, J. P., & Pratley, R. E. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14691 · Cited by 10
“gov identifier: NCT01986881) was a multicentre, randomized, double-blind, placebo-controlled, parallel-group, event-driven study.(10,12) Participants were eligible if they were aged ≥40 years with T2DM (glycated haemoglobin [HbA1c] 53-91 mmol/ mol [7.”
BackgroundMethodResultSelf-citationCherney, D. Z. I., Dagogo-Jack, S. E., Cosentino, F., Pratley, R. E., Frederich, R. C., Maldonado, M., Liu, C., & Cannon, C. P. (2022) · Kidney International Reports · doi:10.1016/j.ekir.2022.05.007 · Cited by 11
“The prespecified secondary outcome of time to first HHF event revealed a 30% relative risk reduction with ertugliflozin versus placebo and a 30% reduction in total HHF events.(6,9) In the VERTIS CV trial, 21.”
BackgroundSelf-citationAberer, F., Pieber, T. R., Eckstein, M. L., Sourij, H., & Moser, O. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14061180 · Cited by 12
Olagunju, A., Yamani, N., Kenny, D., Mookadam, M., Mookadam, F., & Unzek, S. (2022) · World Journal of Cardiology · doi:10.4330/wjc.v14.i11.599 · Cited by 13
Rossing, P. R., Caramori, M. L., Chan, J. C. N., & Al., E. (2023) · KIDNEYS · doi:10.22141/2307-1257.11.4.2022.386 · Cited by 10
Ge, S., Liu, R., Mao, Y.-C., Geng, C., Wang, H., Song, K., & Tian, Q. (2023) · International Heart Journal · doi:10.1536/ihj.22-441 · Cited by 12
Sodium-Glucose Co-Transporter 2 Inhibitors in Heart Failure—Current Evidence in Special Populations
Moady, G., Gal, T. B., & Atar, S. (2023) · Life · doi:10.3390/life13061256 · Cited by 12
“Positive cardiovascular effect was also observed in the CANVAS (canagliflozin and cardiovascular and renal events in type 2 diabetes) trial at the expense of increased risk of limb amputations, while the VERTIS-CV (cardiovascular outcomes with ertugliflozin in type 2 diabetes) trial failed to show that ertugliflozin h…”
BackgroundNani, A., Carrara, F., Paulesu, C. M. E., Fratte, C. D., Padroni, M., Enisci, S., Bilancio, M. C., Romio, M. S., Bertuzzi, F., & Pintaudi, B. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12123958 · Cited by 10
“SGLT2-i = sodium-glucose cotransporter 2 inhibitor(s); M-H = Mantel-Haenszel; CI = confidence interval [4,6,7,23,24,33,42,46,56,58].”
BackgroundInfluentialJürgens, M., Schou, M., Hasbak, P., Kjær, A., Wolsk, E., Zerahn, B., Brandt, N., Gæde, P., Rossing, P. R., Faber, J. O., et al. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15183 · Cited by 11
Bodini, S., Pieralice, S., D’Onofrio, L., Mignogna, C., Coraggio, L., Amendolara, R., Risi, R., Salducci, M., Buzzetti, R., & Maddaloni, E. (2024) · Clinical Therapeutics · doi:10.1016/j.clinthera.2024.04.009 · Cited by 13
Metadata
- Authors
- Cannon, C. P., Pratley, R., Dagogo-Jack, S., Mancuso, J., Huyck, S., Masiukiewicz, U., Charbonnel, B., Frederich, R., Gallo, S., Cosentino, F., Shih, W. J., Gantz, I., Terra, S. G., Cherney, D. Z. I., & McGuire, D. K.
- Affiliations
- Rutgers, The State University of New Jersey (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-10-08
- Volume
- 383
- Issue
- 15
- Pages
- 1425-1435
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3089283105
- Cited by
- 1,514
- References
- 14
- Citations by year
- 2026: 126 · 2025: 177 · 2024: 231 · 2023: 269 · 2022: 298 · 2021: 364 · 2020: 47
- FWCI
- 184.60
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Funders
- Pfizer
- Merck
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- ertugliflozin, SGLT2 inhibitors, type 2 diabetes, atherosclerotic cardiovascular disease, major adverse cardiovascular events, heart failure hospitalization, cardiovascular mortality, non-inferiority, renal safety, non-inferiority margin, myocardial infarction, stroke, renal replacement therapy, serum creatinine doubling, cardiovascular risk stratification
- MeSH terms
- Sodium-Glucose Transporter 2 Inhibitors, Aged, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Diabetic Nephropathies, Double-Blind Method, Female, Hospitalization, Humans, Male, Middle Aged, Placebos, Bridged Bicyclo Compounds, Heterocyclic, Atherosclerosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.